Rankings
▼
Calendar
XLO
Xilio Therapeutics, Inc.
$29M
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$21M
Net Income
-$21M
EPS (Diluted)
$-0.78
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$13M
Stock-Based Comp.
$366,000
Balance Sheet
Total Assets
$36M
Total Liabilities
$42M
Stockholders' Equity
-$5M
Cash & Equivalents
$19M
← FY 2020
All Quarters
Q1 2021 →
XLO Q4 2020 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
